Search Results
May 25, 2026, 06:44 ET Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
(BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast
More news about: Menarini Industrie Farmaceutiche Riunite
May 21, 2026, 08:00 ET Staffmark Group Total Talent Solutions Recognized Among Industry's Top MSP Providers for 2026
looking for workforce partners that can deliver both agility and long-term strategy. Staffmark Group Total Talent Solutions, formerly known as Advantage xPO, has been recognized on the 2026 HRO Today MSP Baker's Dozen list, one of the staffing industry's most respected rankings based entirely on client feedback.
More news about: Staffmark Group
May 14, 2026, 07:30 ET Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
202-211 About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology
More news about: Karyopharm Therapeutics Inc.
May 12, 2026, 07:30 ET Karyopharm to Participate at Upcoming Investor Conferences
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in two oncology indications. It has also received regulatory
More news about: Karyopharm Therapeutics Inc.
May 07, 2026, 07:30 ET Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in two oncology indications. It has also received regulatory
More news about: Karyopharm Therapeutics Inc.
Apr 24, 2026, 10:02 ET From Interconnect to Power and Thermal Management: Luxshare-ICT Expands Its Role in AI Data Center Infrastructure
layers of the data center network. Based on this view, Luxshare-ICT is developing a broader "copper plus optical" portfolio, including CPC, NPC, XPO, NPO and CPO-related technologies. This approach gives the Company flexibility to support different customer architectures rather than relying on a single
More news about: Luxshare Precision Industry Co., Ltd.
Apr 24, 2026, 09:55 ET From Interconnect to Power and Thermal Management: Luxshare-ICT Expands Its Role in AI Data Center Infrastructure
layers of the data center network. Based on this view, Luxshare-ICT is developing a broader "copper plus optical" portfolio, including CPC, NPC, XPO, NPO and CPO-related technologies. This approach gives the Company flexibility to support different customer architectures rather than relying on a single
More news about: Luxshare Precision Industry Co., Ltd.
Apr 21, 2026, 10:39 ET Lambda Supply Chain brings design and optimization software to Gartner® Supply Chain Symposium/Xpo™ 2026
Pia Orup Lund, 16 February 2026GARTNER and Supply Chain Symposium/Xpo are trademark of Gartner, Inc. and/or its affiliates.Gartner does not endorse any company, vendor, product or service depicted in its publications,
More news about: Lambda Supply Chain
Apr 21, 2026, 10:32 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
(2023)About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology
More news about: Karyopharm Therapeutics Inc.
Mar 24, 2026, 07:01 ET Karyopharm Announces $30 Million Private Placement with RA Capital
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory
More news about: Karyopharm Therapeutics Inc.
Mar 24, 2026, 07:00 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
(2023)About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology
More news about: Karyopharm Therapeutics Inc.
Mar 23, 2026, 06:15 ET Women In Trucking Association Names 2026 Top Women to Watch in Trucking
Estes Express LinesSophia Bernard, member partner, Taylor Nelson Slattery Bernard PLMolly Borkgren, enterprise account executive, 3PL, XPO, Inc.Gina Bowker, PDC manager – Renton, PACCAR PartsLesley Boyd, VP, operations & dedicated implementation, Lew Thompson and Son
More news about: Women In Trucking Association, Inc.
Mar 18, 2026, 09:30 ET Two Linktel 800G Dispersion Managed Transceivers Win 2026 Lightwave Innovation Awards
Angeles, Linktel will showcase its latest advancements at Booth #1219. Live demonstrations will feature the award-winning modules, 12.8T Liquid-Cooled XPO, 200G/lane 1.6T modules, and 400G/lane Optical Engines. Linktel invites all industry partners to explore the future of high-speed AI networking at our
More news about: Linktel Technologies
Mar 17, 2026, 08:45 ET Molex Accelerates AI Cluster Deployment with One-Stop Optical Interconnect Architecture and Debut of High-Radix Optical Circuit Switch Platform
XPO interconnect solution at both the Arista booth (#1571) and the Molex booth (#1749) at OFC 2026, supporting the working group addressing AI data center
More news about: Molex Incorporated
Mar 17, 2026, 02:48 ET Linktel, Founding Member of XPO MSA, to Debut 12.8T Liquid-Cooled Module at OFC 2026
development and manufacturing, today announced its 12.8T XPO liquid-cooled optical module will be featured in live demonstrations at OFC 2026. Designed for the escalating density and thermal demands of next-generation data centers, the 64-channel XPO module supports scale-up, scale-out, scale-across, and
More news about: Linktel Technologies
Mar 16, 2026, 10:00 ET Eoptolink Demos Its NX200 and NX300 Series Optical Circuit Switching (OCS) Solution at OFC 2026
significantly higher GPU utilization for our customers."Eoptolink will be showcasing its NX200/300 Optical Circuit Switch (OCS) products, alongside 12.8T XPO, 6.4T NPO, 400G/lambda-1.6T DR4 and 200G/lambda-1.6T FRO/LRO/LPO series optical transceiver solutions, at the Eoptolink booth #1211 at OFC 2026, Los
More news about: Eoptolink Technology Inc., Ltd.
Mar 13, 2026, 10:00 ET Eoptolink Unveils High-Density 6.4T NPO Solution at OFC 2026
centers, delivering high bandwidth, improved density, and outstanding energy efficiency."Eoptolink will be showcasing its latest 6.4T NPO, 12.8T XPO, 400G/lambda-1.6T DR4, and 200G/lambda-1.6T FRO/LRO/LPO series optical transceiver solutions at the Eoptolink booth (#1211) during OFC 2026 in Los Angeles,
More news about: Eoptolink Technology Inc., Ltd.
Mar 12, 2026, 10:00 ET Eoptolink Joins XPO MSA and Unveils Industry-First 12.8 Tbps Liquid-Cooled Pluggable Optics for AI Data Centers
operators rely on."Eoptolink has also joined the XPO Multi-Source Agreement (MSA) as a founding member. The XPO MSA is an industry collaboration focused on defining a new class of high-density, liquid-cooled pluggable optics. By joining the XPO MSA, Eoptolink will contribute its expertise in high-speed
More news about: Eoptolink Technology Inc., Ltd
Mar 12, 2026, 10:00 ET Eoptolink Demos IMDD 400G per Lambda Based 1.6T DR4 Optical Transceiver Solution at OFC 2026
switches to better understand the system requirements for these next-generation optical interfaces."Eoptolink will be showcasing its latest 12.8T XPO, 400G/lambda-1.6T DR4 and 200G/lambda-1.6T FRO/LRO/LPO series optical transceiver solutions, at the Eoptolink booth #1211 during OFC 2026, Los Angeles,
More news about: Eoptolink Technology Inc., Ltd.
Mar 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received
More news about: Karyopharm Therapeutics Inc.
Mar 01, 2026, 19:30 ET XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM).- In South Korea, XPOVIO® has been approved for three indications across
More news about: Antengene Corporation Limited
Feb 25, 2026, 07:00 ET Joint U.S. Commercialization of RedHill's Talicia® Commences
[email protected] Category: Corporate [1] IQVIA XPO Data on file[2] Hooi JKY et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology
More news about: RedHill Biopharma Ltd.
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
202-211 About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology
More news about: Karyopharm Therapeutics Inc.
Feb 05, 2026, 07:30 ET Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received
More news about: Karyopharm Therapeutics Inc.
Feb 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received
More news about: Karyopharm Therapeutics Inc.